Trends in tolvaptan prescription and the association between hypernatremia and aging in tolvaptan-treated patients in Japan: Real-world data mining using Japanese databases.

IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY International journal of clinical pharmacology and therapeutics Pub Date : 2023-01-01 DOI:10.5414/CP204307
Takaya Uno, Kouichi Hosomi, Satoshi Yokoyama, Kazuyoshi Kawabata
{"title":"Trends in tolvaptan prescription and the association between hypernatremia and aging in tolvaptan-treated patients in Japan: Real-world data mining using Japanese databases.","authors":"Takaya Uno,&nbsp;Kouichi Hosomi,&nbsp;Satoshi Yokoyama,&nbsp;Kazuyoshi Kawabata","doi":"10.5414/CP204307","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To identify the trends in tolvaptan prescription and the association between aging and tolvaptan-induced hypernatremia.</p><p><strong>Materials and methods: </strong>A health insurance claims database and a spontaneous adverse drug reaction database were used.</p><p><strong>Results: </strong>Of all patients who had been prescribed tolvaptan, the proportion of patients aged 60 - 79 years and ≥ 80 years was consistent at ~ 40%. Moreover, the prescription frequency of tolvaptan increased over time for patients in the same age groups. The adjusted reporting odds ratio of tolvaptan-induced hypernatremia was 5.54 (95% confidence interval, 3.31 - 9.25) in patients aged ≥ 60 years from among all patients and 2.09 (95% confidence interval, 1.59 - 2.75) in those aged ≥ 80 years from among those aged ≥ 60 years.</p><p><strong>Conclusion: </strong>It may be necessary to be aware of hypernatremia in elderly patients who are expected to have increased prescriptions of tolvaptan.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 1","pages":"33-36"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical pharmacology and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CP204307","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To identify the trends in tolvaptan prescription and the association between aging and tolvaptan-induced hypernatremia.

Materials and methods: A health insurance claims database and a spontaneous adverse drug reaction database were used.

Results: Of all patients who had been prescribed tolvaptan, the proportion of patients aged 60 - 79 years and ≥ 80 years was consistent at ~ 40%. Moreover, the prescription frequency of tolvaptan increased over time for patients in the same age groups. The adjusted reporting odds ratio of tolvaptan-induced hypernatremia was 5.54 (95% confidence interval, 3.31 - 9.25) in patients aged ≥ 60 years from among all patients and 2.09 (95% confidence interval, 1.59 - 2.75) in those aged ≥ 80 years from among those aged ≥ 60 years.

Conclusion: It may be necessary to be aware of hypernatremia in elderly patients who are expected to have increased prescriptions of tolvaptan.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
日本托伐普坦治疗患者的处方趋势和高钠血症与衰老之间的关系:使用日本数据库的真实世界数据挖掘。
目的:了解托伐普坦处方变化趋势及衰老与托伐普坦致高钠血症的关系。材料和方法:使用健康保险索赔数据库和自发药物不良反应数据库。结果:在所有处方托伐普坦的患者中,60 - 79岁和≥80岁的患者比例一致,为~ 40%。此外,在同一年龄组的患者中,托伐普坦的处方频率随时间而增加。在所有患者中,年龄≥60岁的患者中,托伐普坦诱导的高钠血症的校正报告优势比为5.54(95%可信区间,3.31 - 9.25),年龄≥80岁的患者中,年龄≥60岁的患者中,tolvaptan诱导的高钠血症的校正报告优势比为2.09(95%可信区间,1.59 - 2.75)。结论:有可能增加托伐普坦处方的老年患者有必要注意高钠血症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.70
自引率
12.50%
发文量
116
审稿时长
4-8 weeks
期刊介绍: The International Journal of Clinical Pharmacology and Therapeutics appears monthly and publishes manuscripts containing original material with emphasis on the following topics: Clinical trials, Pharmacoepidemiology - Pharmacovigilance, Pharmacodynamics, Drug disposition and Pharmacokinetics, Quality assurance, Pharmacogenetics, Biotechnological drugs such as cytokines and recombinant antibiotics. Case reports on adverse reactions are also of interest.
期刊最新文献
Identification of factors associated with vancomycin-induced acute kidney injury: A retrospective analysis using the Common Data Model. Retrospective evaluation of medical information for predicting tazobactam/piperacillin-induced liver injury. A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system. Positive effects of magnesium supplementation in metabolic syndrome. Corrigendum for the article Int J Clin Pharmacol Ther 2024; 11: 525-533.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1